Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: phytocannabinoid-based ocular therapeutics - InMed Pharmaceuticals

Alternative Names: CTI-085; INM 085

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals; University of Debrecen
  • Class Cannabinoids; Eye disorder therapies
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma
  • Research Hypersensitivity

Most Recent Events

  • 12 Sep 2017 InMed Pharmaceuticals files provisional patent application with US Patent and Trademark Office for E. coli-based expression system for biosynthesis of cannabinoids in USA
  • 10 May 2017 InMed Pharmaceuticals files for patent protection for INM 085 in USA
  • 23 Mar 2015 InMed Pharmaceuticals receives exemption from Health Canada for using phytocannabinoids for research and preclinical studies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top